方盛制药控股子公司芙雅生物股东结构变更香港同盛减资退出

财中社2025-05-08

5月8日，方盛制药（603998）发布公告，控股子公司芙雅生物的股东结构发生变更。根据公告，香港同盛通过减资的方式退出对芙雅生物的全部投资，减资分配的资产为无形资产，账面价值为2050万元。同时，芙雅生物将放弃应付的货款及相关债权，交易预计将产生50万元的投资损失，资本公积减少1909万元。此次股东结构调整是由于公司与香港同盛在芙雅生物的未来发展战略和商业理念上存在差异。交易完成后，芙雅生物将成为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2533327189?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-08 18:25","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2533327189","market":"sh","top_or_hot":-1,"title":"方盛制药控股子公司芙雅生物股东结构变更 香港同盛减资退出","media":"财中社","content":"<div>\n<p>5月8日，方盛制药（603998）发布公告，控股子公司芙雅生物的股东结构发生变更。根据公告，香港同盛通过减资的方式退出对芙雅生物的全部投资，减资分配的资产为无形资产，账面价值为2050万元。同时，芙雅生物将放弃应付的货款及相关债权，交易预计将产生50万元的投资损失，资本公积减少1909万元。此次股东结构调整是由于公司与香港同盛在芙雅生物的未来发展战略和商业理念上存在差异。交易完成后，芙雅生物将成为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505081825179753197a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>方盛制药控股子公司芙雅生物股东结构变更 香港同盛减资退出</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n方盛制药控股子公司芙雅生物股东结构变更 香港同盛减资退出\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-08 18:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505081825179753197a&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月8日，方盛制药（603998）发布公告，控股子公司芙雅生物的股东结构发生变更。根据公告，香港同盛通过减资的方式退出对芙雅生物的全部投资，减资分配的资产为无形资产，账面价值为2050万元。同时，芙雅生物将放弃应付的货款及相关债权，交易预计将产生50万元的投资损失，资本公积减少1909万元。此次股东结构调整是由于公司与香港同盛在芙雅生物的未来发展战略和商业理念上存在差异。交易完成后，芙雅生物将成为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505081825179753197a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505081825179753197a&s=b","article_id":"2533327189","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505081825179753197a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2533327189","pubTimestamp":1746699902,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月8日，方盛制药发布公告，控股子公司芙雅生物的股东结构发生变更。根据公告，香港同盛通过减资的方式退出对芙雅生物的全部投资，减资分配的资产为无形资产，账面价值为2050万元。此次股东结构调整是由于公司与香港同盛在芙雅生物的未来发展战略和商业理念上存在差异。交易完成后，芙雅生物将成为公司的全资子公司。2025年一季度，方盛制药实现收入4.18亿元，归母净利润8826万元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603998":"方盛制药","BK0239":"医药制造","BK0060":"抗癌"},"translate_title":"Changes in shareholder structure of Fuya Biotech, a subsidiary of Fangsheng Pharmaceutical, Hong Kong Tongsheng reduces capital and withdraws","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603998":1},"content_text":"5月8日，方盛制药（603998）发布公告，控股子公司芙雅生物的股东结构发生变更。根据公告，香港同盛通过减资的方式退出对芙雅生物的全部投资，减资分配的资产为无形资产，账面价值为2050万元。同时，芙雅生物将放弃应付的货款及相关债权，交易预计将产生50万元的投资损失，资本公积减少1909万元。此次股东结构调整是由于公司与香港同盛在芙雅生物的未来发展战略和商业理念上存在差异。交易完成后，芙雅生物将成为公司的全资子公司。尽管部分事项涉及关联交易，但不构成重大资产重组。公告中提到，芙雅生物目前仍处于亏损阶段，未来销售效果存在不确定性，投资者需注意相关风险。2025年一季度，方盛制药实现收入4.18亿元，归母净利润8826万元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2533327189","isCrawlerRequest":true}

方盛制药控股子公司芙雅生物股东结构变更 香港同盛减资退出

精彩评论

方盛制药控股子公司芙雅生物股东结构变更香港同盛减资退出